* "concerned about recent stories in some publications about
the FDA's observation report"
Read more
Saturday, April 30, 2016
Buffett, Munger slam Valeant; drugmaker turned into 'a sewer'
NEW YORK, April 30 (Reuters) - Warren Buffett and Charlie
Munger made clear that they are no fans of embattled drugmaker
Valeant Pharmaceuticals International Inc .
Read more
Munger made clear that they are no fans of embattled drugmaker
Valeant Pharmaceuticals International Inc .
Read more
Friday, April 29, 2016
BRIEF-Anthera Pharma amends purchase agreement with Lincoln Park Capital
* On april 27, 2016, Co, Lincoln Park Capital Fund, LLC
entered amendment to purchase agreement, dated as of march 12,
2015
Read more
entered amendment to purchase agreement, dated as of march 12,
2015
Read more
BRIEF-Moody's says Alere's receipt of lender approval for amendment is a positive development
* Alere's receipt of lender approval for amendment and
waiver is a positive development; ratings unaffected
Source text (http://bit.ly/1VYiBej)
(Bengaluru Newsroom; +1 646 223 8780; )
Read more
waiver is a positive development; ratings unaffected
Source text (http://bit.ly/1VYiBej)
(Bengaluru Newsroom; +1 646 223 8780; )
Read more
BRIEF-Harvard Bioscience Q4 non-GAAP earnings per share $0.03
* Reports Fourth Quarter And Year-End 2015 results,
preliminary first quarter 2016 revenues and 2016 financial
guidance
Read more
preliminary first quarter 2016 revenues and 2016 financial
guidance
Read more
BRIEF-Agile Therapeutics says Caxton Corp reports 5.4 pct passive stake in company
* Caxton Corporation reports 5.4 percent passive stake in
Agile Therapeutics Inc as of April 27, 2016 - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Agile Therapeutics Inc as of April 27, 2016 - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Amicus Therapeutics files for potential mixed shelf
* Files for potential mixed shelf; size not disclosed - sec
filing
Source text [http://1.usa.gov/1roaqvt]
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
filing
Source text [http://1.usa.gov/1roaqvt]
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Manitex says affiliate, Ortho Regenerative, has filed final prospectus
* Manitex Capital Inc announces that its affiliate, Ortho
Regenerative Technologies Inc, has filed a final prospectus
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Regenerative Technologies Inc, has filed a final prospectus
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Visiomed FY net loss group share widens to 7.3 million euros
* FY net loss group share of EUR 7.3 million ($8.35
million) versus loss of EUR 2.6 million year ago
Read more
million) versus loss of EUR 2.6 million year ago
Read more
BRIEF-Catalent says new order lifts suspension of pharmaceutical operations
* Softgel manufacturing facility received order from
L'agence National De Sécurité Du Médicament Et Des Produits De
Santé
Read more
L'agence National De Sécurité Du Médicament Et Des Produits De
Santé
Read more
BRIEF-Biocept announces pricing of $5 mln public offering
* Biocept, inc. Announces pricing of $5 million public
offering of common stock and warrants
Read more
offering of common stock and warrants
Read more
BRIEF-Quebec regulator receives Valeant request to lift cease-trade order
April 29 (Reuters) - Valeant Pharmaceuticals International
Inc has requested that Quebec securities regulator
Autorite des Marches Financiers lift its cease-trade order
against directors and key officers
Read more
Inc has requested that Quebec securities regulator
Autorite des Marches Financiers lift its cease-trade order
against directors and key officers
Read more
BRIEF-Janssen's Imbruvica receives CHMP opinion for use in lymphocytic leukaemia patients
* Janssen's Imbruvica (ibrutinib) receives positive CHMP
opinion for expanded use in previously untreated chronic
lymphocytic leukaemia patients
Read more
opinion for expanded use in previously untreated chronic
lymphocytic leukaemia patients
Read more
Sanofi says committed to Medivation takeover
PARIS, April 29 (Reuters) - Sanofi said on Friday
it remained committed to acquiring U.S. drug firm Medivation
and that it was ready to speak directly to its
shareholders.
Read more
it remained committed to acquiring U.S. drug firm Medivation
and that it was ready to speak directly to its
shareholders.
Read more
BRIEF-Neumodx Molecular raises about $20 mln in equity financing
* Files To Say It Raised About $20 Mln In Equity Financing -
Sec filing
Source text: (http://1.usa.gov/1r1JPDY)
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Sec filing
Source text: (http://1.usa.gov/1r1JPDY)
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Hill-Rom qtrly earnings per diluted share of $0.33
* Rom reports higher year-over-year revenue and adjusted
earnings and updates full year outlook
Read more
earnings and updates full year outlook
Read more
BRIEF-Eifelhoehen Klinik FY net loss 0.97 million euros
* FY group revenue 45.98 million euros ($52.32 million) versus 42.81 million euros year ago
Read more
Read more
BRIEF-Shinva Medical Instrument to raise up to 2.2 bln yuan in private placement
* Says it plans to raise up to 2.2 billion yuan ($339.39
million) in private placement of shares to fund projects,
replenish capital
Read more
million) in private placement of shares to fund projects,
replenish capital
Read more
German stocks - Factors to watch on April 29
FRANKFURT, April 29 - The DAX top-30 index looked
set to open 0.8 percent lower on Friday, according to premarket
data from brokerage Lang & Schwarz at 0619 GMT.
Read more
set to open 0.8 percent lower on Friday, according to premarket
data from brokerage Lang & Schwarz at 0619 GMT.
Read more
Thursday, April 28, 2016
BRIEF-Ampliphi Biosciences files for stock shelf of up to $75 mln
* Files for stock shelf of up to $75 million - sec filing
Source text: http://1.usa.gov/1SwOqZu
Further company coverage:
Read more
Source text: http://1.usa.gov/1SwOqZu
Further company coverage:
Read more
BRIEF-Medivation CEO total 2015 compensation $9.6 million
* Ceo david hung's total 2015 compensation $9.6 million
versus $10.6 million in 2014
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
versus $10.6 million in 2014
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
U.S. military punishes 16 over 2015 Afghan hospital bombing
WASHINGTON, April 28 (Reuters) - The U.S. military will
announce on Friday that has it taken disciplinary action against
16 service members over a deadly Oct. 3 air strike in
Afghanistan that destroyed a hospital run by the international
medical charity Medecins Sans Frontieres, U.S. officials tell
Reuters.
Read more
announce on Friday that has it taken disciplinary action against
16 service members over a deadly Oct. 3 air strike in
Afghanistan that destroyed a hospital run by the international
medical charity Medecins Sans Frontieres, U.S. officials tell
Reuters.
Read more
UPDATE 3-AbbVie forges deeper into cancer, as clock ticks for Humira
April 28 (Reuters) - AbbVie Inc placed another big
bet on new cancer drugs on Thursday with a $5.8 billion
acquisition that could lessen its dependence on arthritis
treatment Humira, the world's top selling drug.
Read more
bet on new cancer drugs on Thursday with a $5.8 billion
acquisition that could lessen its dependence on arthritis
treatment Humira, the world's top selling drug.
Read more
UPDATE 3-Bristol raises 2016 forecast after earnings beat
April 28 (Reuters) - Bristol-Myers Squibb Co
ratcheted up its 2016 profit view after trouncing first-quarter
sales and earnings forecasts on strong demand for its new Opdivo
immuno-oncology drug and Eliquis blood clot preventer.
Read more
ratcheted up its 2016 profit view after trouncing first-quarter
sales and earnings forecasts on strong demand for its new Opdivo
immuno-oncology drug and Eliquis blood clot preventer.
Read more
US condemns Syria hospital attack, urges Russia to use influence with Damascus
WASHINGTON, April 28 (Reuters) - The U.S. State Department
said on Thursday that Syria's air strike on a hospital in Aleppo
was "reprehensible," and it called on Russia to use its
influence to pressure Syrian President Bashar al-Assad's
government to stop the attacks.
Read more
said on Thursday that Syria's air strike on a hospital in Aleppo
was "reprehensible," and it called on Russia to use its
influence to pressure Syrian President Bashar al-Assad's
government to stop the attacks.
Read more
BRIEF-Immunotec nominates Mario Paradis to its board of directors
* Immunotec announces the nomination of Mario Paradis to its
board of directors and reports AGM results
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
board of directors and reports AGM results
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-Aduro Biotech announces key preclinical data published
* Aduro Biotech announces key preclinical data published
highlighting new approach to treat multiple myeloma
Read more
highlighting new approach to treat multiple myeloma
Read more
BRIEF-Celgene says 2020 Revlimid forecast is conservative: conf call
April 28 (Reuters) - Celgene Execs Say Otezla Continues To
Grow At Similar Rate After Novartis' Cosentyx Launch - Conf Call
Read more
Grow At Similar Rate After Novartis' Cosentyx Launch - Conf Call
Read more
BRIEF-Biotage Q1 operating profit rises to SEK 24 mln
* Q1 operating profit SEK 23.6 mln (18.0)
Source text for Eikon:
Further company coverage:
(Stockholm Newsroom)
Read more
Source text for Eikon:
Further company coverage:
(Stockholm Newsroom)
Read more
EU mergers and takeovers (April 28)
BRUSSELS, April 28 (Reuters) - The following are mergers
under review by the European Commission and a brief guide to the
EU merger process:
Read more
under review by the European Commission and a brief guide to the
EU merger process:
Read more
UPDATE 1-Celgene revenue rises less than expected due to strong dollar
April 28 (Reuters) - U.S. biotechnology company Celgene Corp
reported first-quarter revenue that fell just shy of
analysts estimates due to the stronger dollar, sending the
company's shares down 1.5 percent in premarket trading.
Read more
reported first-quarter revenue that fell just shy of
analysts estimates due to the stronger dollar, sending the
company's shares down 1.5 percent in premarket trading.
Read more
Bristol raises 2016 forecast after first-quarter earnings beat
April 28 (Reuters) - Bristol-Myers Squibb ratcheted
up its 2016 profit view after trouncing first-quarter sales and
earnings forecasts, driven by demand for its new Opdivo
immuno-oncology drug and its Eliquis blood clot preventer.
Read more
up its 2016 profit view after trouncing first-quarter sales and
earnings forecasts, driven by demand for its new Opdivo
immuno-oncology drug and its Eliquis blood clot preventer.
Read more
BRIEF-Abbott to acquire St. Jude medical
* Transaction expected to be accretive to abbott's adjusted
earnings per share(1) in first full year after closing and
increasing thereafter
Read more
earnings per share(1) in first full year after closing and
increasing thereafter
Read more
OFFICIAL CORRECTION-UBS, MPM team up on $471 mln cancer fund to speed drug development
ZURICH, April 27 (Reuters) - A $471 million UBS
venture fund aims to generate annual returns "north of 10
percent" for its European and Asian investors by financing new
cancer drugs, helping speed them from the lab to the point where
drug companies buy their rights.
Read more
venture fund aims to generate annual returns "north of 10
percent" for its European and Asian investors by financing new
cancer drugs, helping speed them from the lab to the point where
drug companies buy their rights.
Read more
BRIEF-Feelgood Svenska signs deal with city of Malmo
* Signs deal with city of Malmo
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Addlife's rights issue fully subscribed
* Rights issue with preferential rights for company's shareholders has been fully subscribed
Read more
Read more
UPDATE 1-Sanofi bids $9.3 bln for U.S. cancer drug firm Medivation
PARIS/LONDON, April 28 (Reuters) - French pharmaceuticals
group Sanofi said on Thursday it had made an offer to
buy U.S. cancer treatment firm Medivation in a deal worth about
$9.3 billion, marking its return to the biotech takeover trail.
Read more
group Sanofi said on Thursday it had made an offer to
buy U.S. cancer treatment firm Medivation in a deal worth about
$9.3 billion, marking its return to the biotech takeover trail.
Read more
Wednesday, April 27, 2016
BRIEF-Brighter to issue 4.6 million shares
* Said on Wednesday made decision to issue 4.6 million shares without preferential rights
for existing shareholders
Read more
for existing shareholders
Read more
BRIEF-Recipharm Q1 operating profit falls
* Recipharm says going forward we expect to see continued
sequential increases in ebitda-margin and significant growth
from announced acquisitions
Source text for Eikon:
Further company coverage:
Read more
sequential increases in ebitda-margin and significant growth
from announced acquisitions
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Vistin Pharma Q1 EBITDA at 11.0 million Norwegian crowns
* Q1 net profit came in at 6.6 million crowns
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Molecular Partners posts net loss of 4.2 million Swiss francs in Q1 2016
* Phase II strategy for MP0250 laid-out, strategy about
immuno-oncology pipeline disclosed, business and financial
outlook 2016 fully confirmed
Read more
immuno-oncology pipeline disclosed, business and financial
outlook 2016 fully confirmed
Read more
DIARY-Malaysia 2016 corporate earnings
Following is a list of release dates for the quarterly earnings
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 16-20
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 16-20
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
BRIEF-Valeant to name 4 new directors as soon as Friday -CNBC, citing DJ
* Valeant to name 4 new directors as soon as Friday as 5
board members step down; departing directors to include
Valueact's Mason Morfit -CNBC, citing DJ
(Bengaluru Newsroom)
Read more
board members step down; departing directors to include
Valueact's Mason Morfit -CNBC, citing DJ
(Bengaluru Newsroom)
Read more
Valeant to name four new directors as soon as Friday -WSJ
April 27 (Reuters) - Drugmaker Valeant Pharmaceuticals
International Inc is expected to name four new
directors as soon as Friday, the Wall Street Journal reported.
Read more
International Inc is expected to name four new
directors as soon as Friday, the Wall Street Journal reported.
Read more
UPDATE 1-Samsung Biologics plans IPO this year, seen worth as much as $2.6 bln
* Aims to be the world's largest contract manufacturer
(Adds company details, biotech market background)
Read more
(Adds company details, biotech market background)
Read more
Charity urges price cut for pneumonia vaccine for poor children
NEW YORK, April 27 (Thomson Reuters Foundation) - Global
charity Medecins Sans Frontieres delivered a petition with
hundreds of thousands of signatures to pharmaceutical giant
Pfizer Inc on Wednesday, asking the drugmaker to slash the price
of its pneumonia vaccine for poor children.
Read more
charity Medecins Sans Frontieres delivered a petition with
hundreds of thousands of signatures to pharmaceutical giant
Pfizer Inc on Wednesday, asking the drugmaker to slash the price
of its pneumonia vaccine for poor children.
Read more
BRIEF-Valeant Chairman Robert Ingram also considering leaving the board- CNBC, citing DJ
* Valeant Chairman Robert Ingram also considering leaving
the board- CNBC, citing dow jones
Further company coverage:
Read more
the board- CNBC, citing dow jones
Further company coverage:
Read more
UPDATE 1-Merck sex discrimination case could be collective action -judge
April 27 (Reuters) - A federal judge has granted preliminary
approval for a lawsuit accusing Merck & Co Inc of
underpaying female sales representatives to go forward as a
collective action.
Read more
approval for a lawsuit accusing Merck & Co Inc of
underpaying female sales representatives to go forward as a
collective action.
Read more
Samsung Biologics plans to list in S.Korea in 2016
SEOUL, April 28 (Reuters) - Samsung Biologics Co Ltd, the
biopharmaceutical contract manufacturing affiliate of Samsung
Group, said on Thursday that it decided to pursue an
initial public offering in South Korea in 2016.
Read more
biopharmaceutical contract manufacturing affiliate of Samsung
Group, said on Thursday that it decided to pursue an
initial public offering in South Korea in 2016.
Read more
UPDATE 3-Ackman, Valeant pledge reforms after spiking drug prices
WASHINGTON/NEW YORK, April 27 (Reuters) - Activist investor
William Ackman promised U.S. lawmakers on Wednesday that he will
urge the board of Valeant Pharmaceuticals to reduce the
high prices of four life-saving drugs that are now at the heart
of two congressional probes.
Read more
William Ackman promised U.S. lawmakers on Wednesday that he will
urge the board of Valeant Pharmaceuticals to reduce the
high prices of four life-saving drugs that are now at the heart
of two congressional probes.
Read more
Valeant to pay new CEO Papa base salary of $1.5 mln
April 27 (Reuters) - Drugmaker Valeant Pharmaceuticals
International Inc's new chief executive, Joseph Papa,
will receive a base salary of $1.5 million, the company said in
a filing on Wednesday.
Read more
International Inc's new chief executive, Joseph Papa,
will receive a base salary of $1.5 million, the company said in
a filing on Wednesday.
Read more
BRIEF-ADMA Biologics announces proposed public offering of common stock
* Adma Biologics announces proposed public offering of
common stock
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
common stock
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
With more cash, we can eliminate malaria within our lifetime - ex-WHO official
LONDON, April 27 (Thomson Reuters Foundation) - Malaria can
be eliminated soon, but only with much more investment, both to
get rid of the disease and to keep it at bay, a former senior
official of the World Health Organization (WHO) said.
Read more
be eliminated soon, but only with much more investment, both to
get rid of the disease and to keep it at bay, a former senior
official of the World Health Organization (WHO) said.
Read more
BRIEF-PCAS to change its corporate name
* Produits Chimiques et Auxiliaires de Synthèse has decided to change its corporate name to
PCAS
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
PCAS
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
UPDATE 1-Pfizer to pay $784.6 million to resolve Wyeth false claims lawsuit
WASHINGTON, April 27 (Reuters) - Pfizer Inc has
agreed to pay $784.6 million to resolve allegations that Wyeth,
which it acquired in 2009, underpaid drug rebates to Medicaid,
the federal health insurance program, the Justice Department
said Wednesday.
Read more
agreed to pay $784.6 million to resolve allegations that Wyeth,
which it acquired in 2009, underpaid drug rebates to Medicaid,
the federal health insurance program, the Justice Department
said Wednesday.
Read more
Fear of Boko Haram deters displaced in Chad from going home - aid agencies
DAKAR, April 27 (Thomson Reuters Foundation) - Fear of new
Boko Haram attacks in the Lake Chad area is discouraging around
100,000 people uprooted by violence from heading home and is
hindering aid operations, agencies said on Wednesday, days after
Chad extended its state of emergency.
Read more
Boko Haram attacks in the Lake Chad area is discouraging around
100,000 people uprooted by violence from heading home and is
hindering aid operations, agencies said on Wednesday, days after
Chad extended its state of emergency.
Read more
BRIEF-Medical Prognosis Institute and Oncology Venture enter three deals on DRP's
* Says has sold three Drug Response Predictors (DRPs) to Oncology Venture for three new
selected compounds combined with MPI'S DRP for anti-cancer treatment
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
selected compounds combined with MPI'S DRP for anti-cancer treatment
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Anthem CEO sees need for more changes in Obamacare marketplace structure
* Anthem CEO says it sees need for more changes in
marketplace structure, such as fewer special enrollment
exceptions
Read more
marketplace structure, such as fewer special enrollment
exceptions
Read more
Health insurer Anthem reports higher revenue on Medicaid enrollments
April 27 (Reuters) - Health insurer Anthem Inc,
which is in the process of buying smaller rival Cigna Corp
, reported a near 6.5 percent rise in quarterly revenue,
as it added more members to its Medicaid plans.
Read more
which is in the process of buying smaller rival Cigna Corp
, reported a near 6.5 percent rise in quarterly revenue,
as it added more members to its Medicaid plans.
Read more
BRIEF-Bionor Pharma announces departure of CEO
* Said on Tuesday David Horn Solomon will leave his position as Chief Executive Officer of
Bionor Pharma, owing to shareholder led change in company strategy
Read more
Bionor Pharma, owing to shareholder led change in company strategy
Read more
Finland's Orion beats market expectations in first quarter
HELSINKI, April 27 (Reuters) - Finnish drug maker Orion
on Wednesday reported better than expected quarterly
results as revenue from its asthma treatment products helped
offset falling sales of its Parkinson's disease drug which faced
increased generic competition.
Read more
on Wednesday reported better than expected quarterly
results as revenue from its asthma treatment products helped
offset falling sales of its Parkinson's disease drug which faced
increased generic competition.
Read more
French and Benelux stocks-Factors to watch on April 27
PARIS, April 27 (Reuters) - Below are company-related news
and stories from French and Benelux media which could have an
impact on the region's markets or individual stocks.
Read more
and stories from French and Benelux media which could have an
impact on the region's markets or individual stocks.
Read more
Tuesday, April 26, 2016
German stocks - Factors to watch on April 27
BERLIN/FRANKFURT, April 27 (Reuters) - The following are
some of the factors that may move German stocks on Wednesday:
Read more
some of the factors that may move German stocks on Wednesday:
Read more
HK Exchange says 12 firms buy back shares
HONG KONG, April 27 (Reuters) - The Hong Kong stock exchange said on Wednesday 12 companies
had repurchased their ordinary shares in the market.
The following is a table regarding share buybacks:
Company Name Stock Code Date of No. of Highest Lowest price
Repurchased Securities price per per share
Repurchased share
--- --- ---
Read more
had repurchased their ordinary shares in the market.
The following is a table regarding share buybacks:
Company Name Stock Code Date of No. of Highest Lowest price
Repurchased Securities price per per share
Repurchased share
--- --- ---
Read more
White House urges Congress to move on Zika funding
WASHINGTON, April 26 (Reuters) - Two senior Obama
administration officials wrote congressional leaders on Tuesday
to urge legislation be passed to fund the fight against the Zika
virus, as concerns mount the United States will soon face
locally transmitted cases of the disease.
Read more
administration officials wrote congressional leaders on Tuesday
to urge legislation be passed to fund the fight against the Zika
virus, as concerns mount the United States will soon face
locally transmitted cases of the disease.
Read more
UPDATE 2-Edwards raises outlook, plans for valve label expansion
April 26 (Reuters) - Edwards Lifesciences Corp on
Tuesday raised its full-year sales and profit outlook following
strong first-quarter results and said approval for expanded use
of its minimally invasive heart valve implant could come sooner
than previously expected.
Read more
Tuesday raised its full-year sales and profit outlook following
strong first-quarter results and said approval for expanded use
of its minimally invasive heart valve implant could come sooner
than previously expected.
Read more
BRIEF-Psychemedics quarterly revenue fell 1 pct to $6.7 mln
* Quarterly earnings per share $0.00
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
UPDATE 4-Cheap oil smudges Exxon's long-held sterling credit rating
April 26 (Reuters) - Exxon Mobil Corp lost its
top-tier credit rating from Standard & Poor's on Tuesday for the
first time in almost 70 years, as slumping crude prices crimp
the oil giant's ability to fund projects and return big amounts
of cash to shareholders.
Read more
top-tier credit rating from Standard & Poor's on Tuesday for the
first time in almost 70 years, as slumping crude prices crimp
the oil giant's ability to fund projects and return big amounts
of cash to shareholders.
Read more
BRIEF-Helius Medical Technologies says necessary to re-evaluate warrants' accounting
* Board says necessary to re-evaluate accounting relating to
warrants issued in private placements in april, june, july 2015
Read more
warrants issued in private placements in april, june, july 2015
Read more
Deals of the day- Mergers and acquisitions
April 26 (Reuters) - The following bids, mergers,
acquisitions and disposals were reported by 2000 GMT on Tuesday:
Read more
acquisitions and disposals were reported by 2000 GMT on Tuesday:
Read more
Edwards Lifesciences raises outlook on strong valve sales
April 26 (Reuters) - Edwards Lifesciences Corp on
Tuesday reported a better-than-expected quarterly profit and
raised its full-year outlook on strong sales of its minimally
invasive heart valve implants.
Read more
Tuesday reported a better-than-expected quarterly profit and
raised its full-year outlook on strong sales of its minimally
invasive heart valve implants.
Read more
BRIEF-Bluelinea FY operating loss narrows to 1.9 million euros
* FY operating loss 1.9 million euros ($2.15 million) versus loss of 2.4 million euros year
ago
Read more
ago
Read more
U.S. House Democrats question if Valeant is wrongfully withholding records
WASHINGTON, April 26 (Reuters) - Democrats on a powerful
U.S. congressional panel are questioning whether Canada-based
Valeant Pharmaceuticals may be wrongfully withholding
documents in connection with its ongoing probe into
sky-rocketing drug prices, according to an internal memo seen by
Reuters on Tuesday.
Read more
U.S. congressional panel are questioning whether Canada-based
Valeant Pharmaceuticals may be wrongfully withholding
documents in connection with its ongoing probe into
sky-rocketing drug prices, according to an internal memo seen by
Reuters on Tuesday.
Read more
BRIEF-Euroespes FY net profit up 16 pct at 207,000 euros yoy
* FY revenue up 11.49 percent at 2.9 million euros ($3.3 million) versus 2.6 million euros
year ago
Read more
year ago
Read more
BRIEF-Quantum genomics receives authorisation to begin Phase IIA multicentric European trial
* Regulatory authorisations received in France to begin Phase IIA multicentric European
trial for heart failure
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
trial for heart failure
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Catalyst pharmaceuticals provides regulatory update on Firdapse
* Catalyst pharmaceuticals provides regulatory update on
firdapse
Source text for Eikon:
Further company coverage:
Read more
firdapse
Source text for Eikon:
Further company coverage:
Read more
UPDATE 2-Lilly earnings fall short, hurt by research spending
April 26 (Reuters) - Eli Lilly and Co on Tuesday
reported lower than expected first quarter earnings due largely
to heavy spending on research, sending its shares 2 percent
lower in premarket trading.
Read more
reported lower than expected first quarter earnings due largely
to heavy spending on research, sending its shares 2 percent
lower in premarket trading.
Read more
UPDATE 1-Baxter lifts 2016 adjusted profit forecast after strong quarter
April 26 (Reuters) - Baxter International Inc
reported a better-than-expected quarterly profit and lifted its
adjusted earnings forecast for 2016.
Read more
reported a better-than-expected quarterly profit and lifted its
adjusted earnings forecast for 2016.
Read more
Baxter's sales dip 1 pct, hurt by strong dollar
April 26 (Reuters) - Baxter International Inc
reported a near 1 percent fall in first-quarter net sales,
constrained by the dollar's strength.
Read more
reported a near 1 percent fall in first-quarter net sales,
constrained by the dollar's strength.
Read more
BRIEF-Exicure announces dosing of first patient in phase 1 trial
* Exicure announces dosing of first patient in phase 1 trial
for the treatment of chronic plaque psoriasis
Source text for Eikon:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
for the treatment of chronic plaque psoriasis
Source text for Eikon:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
China to give 2 bln yuan in subsidies to public hospitals in 100 trial cities
BEIJING, April 26 (Reuters) - China will offer 2 billion
yuan, or $308 million, in subsidies to public hospitals in 100
trial cities, the State Council, or cabinet, said in an
announcement on 2016 health care reform goals on Tuesday.
Read more
yuan, or $308 million, in subsidies to public hospitals in 100
trial cities, the State Council, or cabinet, said in an
announcement on 2016 health care reform goals on Tuesday.
Read more
BRIEF-AstraZeneca, Ironwood agree U.S. licensing agreement
* Agreement includes U.S. rights to zurampic and
lesinurad/allopurinol fixed-dose combination in gout
Read more
lesinurad/allopurinol fixed-dose combination in gout
Read more
BRIEF-Sarepta statement on advisory committee outcome for use of Eteplirsen in treatment of Duchenne muscular dystrophy
* Sarepta issues statement on advisory committee outcome for
use of Eteplirsen in treatment of duchenne muscular dystrophy
Read more
use of Eteplirsen in treatment of duchenne muscular dystrophy
Read more
UPDATE 1-Nokia to buy health tracking firm Withings
HELSINKI, April 26 (Reuters) - Finnish mobile network
equipment maker Nokia said on Tuesday it had struck a
deal to buy France's Withings S.A. for 170 million euros ($191
million) in its first move into the market for digital products
that monitor health.
Read more
equipment maker Nokia said on Tuesday it had struck a
deal to buy France's Withings S.A. for 170 million euros ($191
million) in its first move into the market for digital products
that monitor health.
Read more
BRIEF-Xvivo Perfusion Q1 EBITDA up at SEK 7.3 million
* Q1 operating income before depreciation and amortization (EBITDA) excluding one-time
expenses amounted to 7.3 million Swedish crowns ($897,357), corresponding to EBITDA margin of 22
percent, versus an EBITDA of 4.5 million crowns a year ago
Read more
expenses amounted to 7.3 million Swedish crowns ($897,357), corresponding to EBITDA margin of 22
percent, versus an EBITDA of 4.5 million crowns a year ago
Read more
BRIEF-Probi signs extensive primary care distribution agreement with Ipsen
* Probi and Ipsen sign extensive primary care distribution agreement for probiotic LP299V,
Lactobacillus plantarum 299v
Read more
Lactobacillus plantarum 299v
Read more
BRIEF-Ipsen partner Exelixis obtains FDA approval of CABOMETYX tablets
* Announces that its partner Exelixis obtained FDA
approval of CABOMETYX (cabozantinib) tablets for patients with
advanced renal cell carcinoma who have received prior
anti-angiogenic therapy
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
approval of CABOMETYX (cabozantinib) tablets for patients with
advanced renal cell carcinoma who have received prior
anti-angiogenic therapy
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Monday, April 25, 2016
Malaria deaths rising in Angola as health crisis spreads
LUANDA, April 26 (Reuters) - Deaths from malaria in Angola
this year look set to outstrip 2015 as a health crisis that
includes one of the country's worst yellow fever outbreaks in
decades spreads, the World Health Organisation said.
Read more
this year look set to outstrip 2015 as a health crisis that
includes one of the country's worst yellow fever outbreaks in
decades spreads, the World Health Organisation said.
Read more
Bayer Q1 adj EBITDA up 16 percent on pharmaceuticals
FRANKFURT, April 26 (Reuters) - Germany drugmaker Bayer
reported 15.7 percent higher underlying core earnings
for the first quarter, boosted by prescription drugs such as eye
treatment Eylea.
Read more
reported 15.7 percent higher underlying core earnings
for the first quarter, boosted by prescription drugs such as eye
treatment Eylea.
Read more
Singapore March factory output dips 0.5 pct y/y, less than expected
SINGAPORE, April 26 (Reuters) - Singapore's industrial
production in March fell less than expected from a year earlier
due to a surge in pharmaceuticals, data showed on Tuesday.
Manufacturing output fell 0.5 percent from a year earlier in
March, data from the Singapore Economic Development Board
showed. The median forecast in a Reuters survey was for a drop
of 2.7 percent.
On a month-on-month and seasonally adjusted basis, factory
output rose 1.0 percent in March, matching the median for
Read more
production in March fell less than expected from a year earlier
due to a surge in pharmaceuticals, data showed on Tuesday.
Manufacturing output fell 0.5 percent from a year earlier in
March, data from the Singapore Economic Development Board
showed. The median forecast in a Reuters survey was for a drop
of 2.7 percent.
On a month-on-month and seasonally adjusted basis, factory
output rose 1.0 percent in March, matching the median for
Read more
German stocks - Factors to watch on April 26
FRANKFURT/BERLIN, April 26 - The following are some of the
factors that may move German stocks on Tuesday:
Read more
factors that may move German stocks on Tuesday:
Read more
Alere receives default notice from bondholder group - Bloomberg
April 25 (Reuters) - Alere Inc received a notice of
default from a group of its bondholders after the diagnostics
company delayed filing its 2015 annual report in March,
Bloomberg reported Monday.
Read more
default from a group of its bondholders after the diagnostics
company delayed filing its 2015 annual report in March,
Bloomberg reported Monday.
Read more
BRIEF-Alere received notice of default from group of bondholders - Bloomberg
* Alere Inc received a notice of default from a group of
bondholders after co delayed filing its 2015 financial statement
- Bloomberg, citing sources
Source text : (http://bloom.bg/1TtAPkC)
Further company coverage:
Read more
bondholders after co delayed filing its 2015 financial statement
- Bloomberg, citing sources
Source text : (http://bloom.bg/1TtAPkC)
Further company coverage:
Read more
UPDATE 6-Valeant names Papa CEO after he resigns from Perrigo
April 25 (Reuters) - Former Perrigo Co Plc head
Joseph Papa was named Chief Executive Officer at Valeant
Pharmaceuticals International on Monday, a role in
which investors said he should focus on returning the company to
growth.
Read more
Joseph Papa was named Chief Executive Officer at Valeant
Pharmaceuticals International on Monday, a role in
which investors said he should focus on returning the company to
growth.
Read more
BRIEF-Verisk Analytics signs definitive agreement to sell its healthcare services business to Veritas Capital for $820 mln
* Verisk analytics, inc., signs definitive agreement to sell
its healthcare services business to Veritas Capital for $820
million
Read more
its healthcare services business to Veritas Capital for $820
million
Read more
BRIEF-Perrigo enters into amendment to employment agreement in connection with Joseph Papa's resignation
* In connection with Papa's resignation, he and co, and
Perrigo Michigan entered into an amendment to employment
agreement
Read more
Perrigo Michigan entered into an amendment to employment
agreement
Read more
Canada confirms first sexually transmitted Zika case
WINNIPEG, Manitoba, April 25 (Reuters) - An Ontario resident is Canada's first confirmed case of a Zika virus infection that was contracted locally through sex, health officials said on Monday.
Read more
Read more
BRIEF-Transition Therapeutics says dosing of first patient in Phase 2 study of drug candidate TT701
* Transition therapeutics announces dosing of first patient
in phase 2 study of drug candidate tt701
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
in phase 2 study of drug candidate tt701
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Txcell and Ospedale San Raffaele to develop CAR-Tregs in Lupus Nephritis
* Txcell and Ospedale San Raffaele launch collaboration for the development of CAR-Tregs in
Lupus Nephritis
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Lupus Nephritis
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
U.S. FDA panel meets to discuss Sarepta muscular dystrophy drug
April 25 (Reuters) - Hundreds of patients and advocates
packed a hotel ballroom in Hyattsville, Maryland on Monday to
try to persuade advisors to the U.S. Food and Drug
Administration to support approval of an experimental drug to
treat Duchenne muscular dystrophy.
Read more
packed a hotel ballroom in Hyattsville, Maryland on Monday to
try to persuade advisors to the U.S. Food and Drug
Administration to support approval of an experimental drug to
treat Duchenne muscular dystrophy.
Read more
BRIEF-Zimmer Biomet to acquire Cayenne Medical
* Entered into a definitive agreement to acquire Scottsdale,
Arizona-based Cayenne Medical, Inc
Read more
Arizona-based Cayenne Medical, Inc
Read more
BRIEF-Tesaro announces submission of investigational new drug application
* Tesaro Announces Submission Of Investigational New Drug
Application For Anti Tim-3 antibody tsr-022 to the u.s. Fda
Read more
Application For Anti Tim-3 antibody tsr-022 to the u.s. Fda
Read more
BRIEF-Fibrocell receives orphan drug designation for FCX-013
* Sats receives orphan drug designation from the FDA for for
FCX-013 for the treatment of localized scleroderma
Read more
FCX-013 for the treatment of localized scleroderma
Read more
BRIEF-Perrigo says Joseph C. Papa resigns as chairman and CEO
* Perrigo appoints John T. Hendrickson as chief executive
officer, provides preliminary first-quarter 2016 selected
financial results, and updates full-year 2016 guidance
Read more
officer, provides preliminary first-quarter 2016 selected
financial results, and updates full-year 2016 guidance
Read more
Deals of the day-Mergers and acquisitions
April 25 (Reuters) - The following bids, mergers,
acquisitions and disposals were reported by 1000 GMT on Monday:
Read more
acquisitions and disposals were reported by 1000 GMT on Monday:
Read more
Novartis discussing Roche stake sale, but not imminent -sources
LONDON/ZURICH, April 25 (Reuters) - Novartis is
discussing options with banks for selling its 13.5 billion Swiss
franc ($13.8 billion) stake in rival Roche, though a
sale is not imminent, according to two people familiar with the
situation.
Read more
discussing options with banks for selling its 13.5 billion Swiss
franc ($13.8 billion) stake in rival Roche, though a
sale is not imminent, according to two people familiar with the
situation.
Read more
BRIEF-Philips says Lighting unit IPO/sale proceeds likely to be used in blended form - conf call
* Says proceeds from IPO or sale of lighting division will
likely be used in a blended form - conference call
Read more
likely be used in a blended form - conference call
Read more
Covestro on track to reach yr-earlier EBITDA levels in Q2 -CFO
FRANKFURT, April 25 (Reuters) - Covestro, the
plastics and chemicals maker that parent Bayer plans
to divest, is confident that second-quarter earnings before
interest, taxes, depreciation and amortisation (EBITDA) will
reach year-earlier levels, its finance chief said.
Read more
plastics and chemicals maker that parent Bayer plans
to divest, is confident that second-quarter earnings before
interest, taxes, depreciation and amortisation (EBITDA) will
reach year-earlier levels, its finance chief said.
Read more
Philips CEO says Lumileds division performance to improve in H2
AMSTERDAM, April 25 (Reuters) - The performance of Philips'
up-for-sale Lumileds lighting components division is
expected to improve in the second part of 2016, CEO Frans van
Houten said on Monday.
Read more
up-for-sale Lumileds lighting components division is
expected to improve in the second part of 2016, CEO Frans van
Houten said on Monday.
Read more
BRIEF-Merck's phase iii tailor landmark study demonstrates significant benefits of Erbitux in combination with FOLFOX over FOLFOX alone
* Says phase iii tailor landmark study demonstrates
significant benefits of erbitux in combination with FOLFOX over
FOLFOX alone
Read more
significant benefits of erbitux in combination with FOLFOX over
FOLFOX alone
Read more
Swiss stocks - Factors to watch on April 25
ZURICH, April 25 (Reuters) - The Swiss blue-chip SMI
was seen opening barely changed at 8110 points on Monday,
according to premarket indications by bank Julius Baer
.
Read more
was seen opening barely changed at 8110 points on Monday,
according to premarket indications by bank Julius Baer
.
Read more
Sunday, April 24, 2016
BRIEF-Koninklijke Philips Q1 comparable sales up 3 pct at EUR 5.5 BLN
* Q1 adjusted EBITA amounted to 374 million euros ($420.34
million), or 6.8 percent of sales, compared to 6.1 percent of
sales in Q1 2015
Read more
million), or 6.8 percent of sales, compared to 6.1 percent of
sales in Q1 2015
Read more
DIARY-Malaysia 2016 corporate earnings
Following is a list of release dates for the quarterly earnings
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 16-20
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 16-20
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
UPDATE 1-Iraq signs strategic agreement with GE to boost power grid
BAGHDAD, April 24 (Reuters) - Iraq's Oil Ministry said on
Sunday it had signed a long-term "strategic framework agreement"
with General Electric which comprised several projects to
boost national power resources.
Read more
Sunday it had signed a long-term "strategic framework agreement"
with General Electric which comprised several projects to
boost national power resources.
Read more
Once a symbol of decline, Pennsylvania tests limits of Trump's appeal
BETHLEHEM, Pa., April 24 (Reuters) - With a rusting steel
mill in its center, this Pennsylvania city would seem fertile
ground for Donald Trump's campaign and its vision of a declining
America that only he can fix.
Read more
mill in its center, this Pennsylvania city would seem fertile
ground for Donald Trump's campaign and its vision of a declining
America that only he can fix.
Read more
Iraq signs strategic agreement with GE to boost power grid
BAGHDAD, April 24 (Reuters) - Iraq's Oil Ministry said on
Sunday it had signed a long-term "strategic framework agreement"
with General Electric which comprised several projects to
boost national power resources.
Read more
Sunday it had signed a long-term "strategic framework agreement"
with General Electric which comprised several projects to
boost national power resources.
Read more
Nearly 50 starving monkeys rescued in South Africa by animal rights group
MULDERSDRIFT, South Africa, April 23 (Reuters) - Close to 50
starved and sick monkeys were rescued from filthy living
conditions in a South African private zoo on Saturday, and were
whisked away to a care facility, an international animal rights
group said.
Read more
starved and sick monkeys were rescued from filthy living
conditions in a South African private zoo on Saturday, and were
whisked away to a care facility, an international animal rights
group said.
Read more
Saturday, April 23, 2016
Valeant gets additional notices of default from bondholders
April 22 (Reuters) - Canadian drugmaker Valeant
Pharmaceuticals International Inc said it received
additional notices of default from its bondholders as a result
of a delay in filing its annual report.
Read more
Pharmaceuticals International Inc said it received
additional notices of default from its bondholders as a result
of a delay in filing its annual report.
Read more
Friday, April 22, 2016
BRIEF-Natus Medical says CEO James Hawkins FY 2015 total compensation $4.5 mln vs $3.8 mln in FY 2014
* Says CEO James B. Hawkins FY 2015 total compensation $4.5
mln vs $3.8 mln in FY 2014 - sec filing
Source text: http://1.usa.gov/1SzHsS0
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
mln vs $3.8 mln in FY 2014 - sec filing
Source text: http://1.usa.gov/1SzHsS0
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-Intellia Therapeutics appoints Perry Karsen as chairman of board
* Intellia therapeutics appoints perry karsen as chairman of
its board of directors
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
its board of directors
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Mettrum files preliminary short form prospectus for $7.5 mln bought deal offering of common shares
* Mettrum announces filing of preliminary short form
prospectus for $7.5 million bought deal offering of common
shares
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
prospectus for $7.5 million bought deal offering of common
shares
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
REFILE-China to ratify Paris climate change deal by September: envoy
UNITED NATIONS, April 22 (Reuters) - China, one of the
world's top emitters of greenhouse gases, pledged on Friday to
ratify the Paris deal to slow climate change by September,
China's Vice Premier Zhang Gaoli said on Friday.
Read more
world's top emitters of greenhouse gases, pledged on Friday to
ratify the Paris deal to slow climate change by September,
China's Vice Premier Zhang Gaoli said on Friday.
Read more
BRIEF-Unitedhealth Group CEO 2015 total compensation $14.5 mln
* CEO Stephen J. Hemsley's 2015 total compensation was $14.5
million versus $14.9 million in 2014 - SEC filing
Read more
million versus $14.9 million in 2014 - SEC filing
Read more
U.S. FAA orders fix for GE engines on up to 150 Boeing 787 jets
NEW YORK, April 22 (Reuters) - The U.S. aviation regulator
on Friday ordered an urgent fix for General Electric
engines on up to 150 Boeing 787 Dreamliners, a step to
avoid conditions that can cause an engine failure in icy
conditions.
Read more
on Friday ordered an urgent fix for General Electric
engines on up to 150 Boeing 787 Dreamliners, a step to
avoid conditions that can cause an engine failure in icy
conditions.
Read more
CORRECTED-Disgruntled investors flex vote muscle on UK executive pay
LONDON, April 22 (Reuters) - Change the way you pay or risk
losing your jobs, corporate governance watchdogs have warned the
boards of Britain's top companies, as investors call for a
reality check on salaries.
Read more
losing your jobs, corporate governance watchdogs have warned the
boards of Britain's top companies, as investors call for a
reality check on salaries.
Read more
U.S. agencies issues rules to protect workers from Zika
CHICAGO, April 22 (Reuters) - U.S. health and safety officials issued new guidelines on Friday to help protect workers from exposure to Zika, a mosquito-borne and sexually-transmitted virus that causes the birth defect microcephaly and other neurological disorders.
Read more
Read more
U.S. FDA staff sets voting questions for Sarepta's muscle drug
April 22 (Reuters) - U.S. Food and Drug Administration staff
on Friday formulated voting questions on Sarepta Therapeutics
Inc's muscle wasting drug, ahead of a highly
anticipated meeting of independent panel of experts on Monday to
review the drug.
Read more
on Friday formulated voting questions on Sarepta Therapeutics
Inc's muscle wasting drug, ahead of a highly
anticipated meeting of independent panel of experts on Monday to
review the drug.
Read more
BRIEF-aap implantate posts 2015 EBITDA loss of 1.9 mln euros
* Annual financial statements 2015: sales at 28 million
euros ($31.48 million) within the guidance
Read more
euros ($31.48 million) within the guidance
Read more
UPDATE 1-U.S. FDA proposes ban on certain electrical stimulation devices
April 22 (Reuters) - The U.S. Food and Drug Administration
on Friday proposed a ban on electrical stimulation devices
(ESDs) that are used to curb individuals from engaging in
self-injurious or aggressive behavior, saying they pose an
"unreasonable and substantial" risk to public health.
Read more
on Friday proposed a ban on electrical stimulation devices
(ESDs) that are used to curb individuals from engaging in
self-injurious or aggressive behavior, saying they pose an
"unreasonable and substantial" risk to public health.
Read more
BRIEF-Corelens to supply materials used for treatment of cataract
* Receives signed agreement with a public hospital for the
delivery of materials used for treatment of cataract
Read more
delivery of materials used for treatment of cataract
Read more
Dividend recap deals return as junk bonds heat up
NEW YORK, April 22 (IFR) - In another sign that the US junk
bond market has turned the corner, syndicate desks are prepping
a number of deals that pay juicy dividends to private equity
sponsors.
Read more
bond market has turned the corner, syndicate desks are prepping
a number of deals that pay juicy dividends to private equity
sponsors.
Read more
Mexico explores regulating opium to fight drug violence
MEXICO CITY, April 22 (Reuters) - Mexico's government has
explored regulating poppy production to make pharmaceutical
opiates like morphine in an effort to weaken heroin-smuggling
gangs, according to two sources with knowledge of the
government's thinking.
Read more
explored regulating poppy production to make pharmaceutical
opiates like morphine in an effort to weaken heroin-smuggling
gangs, according to two sources with knowledge of the
government's thinking.
Read more
China to ratify Paris climate change deal by September: envoy
UNITED NATIONS, April 22 (Reuters) - China, one of the
world's top emitters of greenhouse gases, pledged on Friday to
ratify the Paris deal to slow climate change by September, a
senior Chinese envoy said on Friday.
Read more
world's top emitters of greenhouse gases, pledged on Friday to
ratify the Paris deal to slow climate change by September, a
senior Chinese envoy said on Friday.
Read more
UPDATE 2-GE profit tops estimates but organic revenue falls 1 percent
NEW YORK, April 22 (Reuters) - General Electric Co
reported a higher-than-expected first-quarter profit on Friday,
but a closely watched revenue measure declined, raising
questions about the company's full-year target.
Read more
reported a higher-than-expected first-quarter profit on Friday,
but a closely watched revenue measure declined, raising
questions about the company's full-year target.
Read more
CANADA STOCKS-Futures rise on higher oil, positive data
April 22 (Reuters) - Stock futures pointed to a higher start
for Canada's main stock index on Friday as oil prices hovered
near $45 per barrel and after Canada's retail sales and
inflation data.
Read more
for Canada's main stock index on Friday as oil prices hovered
near $45 per barrel and after Canada's retail sales and
inflation data.
Read more
BRIEF-Intrexon provides update on recent stock trading activity
* On thursday, a report regarding company, its subsidiaries
and its chairman and ceo was published a financial blog
Read more
and its chairman and ceo was published a financial blog
Read more
BRIEF-GE posts Q1 operating earnings per share $0.06
* Q1 earnings per share view $0.19, revenue view $27.62
billion -- Thomson Reuters I/B/E/S
Source text (http://invent.ge/1MMuWQ1)
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
billion -- Thomson Reuters I/B/E/S
Source text (http://invent.ge/1MMuWQ1)
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
UPDATE 1-UK Stocks-Factors to watch on April 22
April 22 (Reuters) - Britain's FTSE 100 index is seen opening lower
32 points, or 0.5 percent, on Friday, according to financial bookmakers, with
futures down 0.4 percent ahead of the cash market open. For more on the
factors affecting European stocks, please click on
Read more
32 points, or 0.5 percent, on Friday, according to financial bookmakers, with
futures down 0.4 percent ahead of the cash market open. For more on the
factors affecting European stocks, please click on
Read more
BRIEF-Lidds Q1 pre-tax loss narrows to SEK 1.5 million
* Q1 pre-tax loss 1.5 million Swedish crowns ($185,000)
versus loss 2.2 million crowns year ago
Source text for Eikon:
Read more
versus loss 2.2 million crowns year ago
Source text for Eikon:
Read more
BRIEF-Cytotools unit signs contracts for production with German manufacturer
* Dermatools Biotech identifies new manufacturers for drug DermaPro, thereby creating the
basis for the repetition of the phase III clinical study
Read more
basis for the repetition of the phase III clinical study
Read more
Thursday, April 21, 2016
BRIEF-Sobi says signs licensing agreement with Affibody for IL-1
* Says exercised its option to sign a licensing agreement
with Swedish biotech company Affibody AB for the development of
novel treatments for inflammatory diseases where interleukin-1
(IL-1) is involved
Source text for Eikon:
Further company coverage:
(Stockholm Newsroom)
Read more
with Swedish biotech company Affibody AB for the development of
novel treatments for inflammatory diseases where interleukin-1
(IL-1) is involved
Source text for Eikon:
Further company coverage:
(Stockholm Newsroom)
Read more
Swiss stocks - Factors to watch on April 22
ZURICH, April 22 (Reuters) - The Swiss blue-chip SMI
was seen opening 0.17 percent lower at 8,145.7 points on Friday,
according to premarket indications by bank Julius Baer
.
Read more
was seen opening 0.17 percent lower at 8,145.7 points on Friday,
according to premarket indications by bank Julius Baer
.
Read more
BRIEF-BB Biotech Q1 net result swings to loss of CHF 1.2 billion
* Reports a net loss of 1.2 billion Swiss francs ($1.23
billion) for Q1 of 2016 compared to a net profit of 379 million
Swiss francs for same period last year
Read more
billion) for Q1 of 2016 compared to a net profit of 379 million
Swiss francs for same period last year
Read more
UK Stocks-Factors to watch on April 22
April 22 (Reuters) - Britain's FTSE 100 index is seen opening down
32 points, or 0.5 percent, on Friday, according to financial bookmakers. For
more on the factors affecting European stocks, please click on
Read more
32 points, or 0.5 percent, on Friday, according to financial bookmakers. For
more on the factors affecting European stocks, please click on
Read more
PRESS DIGEST- Financial Times - April 22
April 22 (Reuters) - The following are the top stories in
the Financial Times. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
the Financial Times. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
BRIEF-Valeant seeks to name Perrigo's Joseph Papa to be new CEO- CNBC citing DJ
* Valeant Pharmaceuticals International seeks to name
Perrigo's Joseph Papa to be new CEO - CNBC citing DJ
Read more
Perrigo's Joseph Papa to be new CEO - CNBC citing DJ
Read more
UK agency backs cancer drug after Sanofi cuts price
LONDON, April 22 (Reuters) - Britain's healthcare cost
watchdog NICE said on Friday it had changed its mind and decided
to recommend Sanofi's prostate cancer drug Jevtana
after the French company agreed to a further discount.
Read more
watchdog NICE said on Friday it had changed its mind and decided
to recommend Sanofi's prostate cancer drug Jevtana
after the French company agreed to a further discount.
Read more
BRIEF-Human Longevity Inc. announces 10 year deal with Astrazeneca
* Human longevity Inc announces 10 year deal with
Astrazeneca to sequence and analyze patient samples from
Astrazeneca clinical trials
Read more
Astrazeneca to sequence and analyze patient samples from
Astrazeneca clinical trials
Read more
BRIEF-Biomarin enrolls first patient in early study of BMN 250 for sanfilippo B syndrome
* Biomarin enrolls first patient in phase 1/2 trial of NAGLU
fusion protein BMN 250 for treatment of MPS IIIB (sanfilippo B
syndrome)
Read more
fusion protein BMN 250 for treatment of MPS IIIB (sanfilippo B
syndrome)
Read more
BRIEF-Humana sets quarterly cash dividend of $0.29/share
* Sets quarterly cash dividend of $0.29per share
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
Fitch Affirms Owens & Minor at 'BBB-'; Outlook Stable
(The following statement was released by the rating agency)
CHICAGO, April 21 (Fitch) Fitch Ratings has affirmed the ratings
of Owens &
Minor, Inc. (NYSE: OMI), including the long-term Issuer Default
Rating (IDR), at
'BBB-'. The Rating Outlook is Stable.
A full list of rating actions, which apply to approximately $580
million at Dec.
31, 2015, follows at the end of this release.
KEY RATING DRIVERS
Strong Market Share: OMI holds a strong share of the steady and
oligopolistic
market for the di
Read more
CHICAGO, April 21 (Fitch) Fitch Ratings has affirmed the ratings
of Owens &
Minor, Inc. (NYSE: OMI), including the long-term Issuer Default
Rating (IDR), at
'BBB-'. The Rating Outlook is Stable.
A full list of rating actions, which apply to approximately $580
million at Dec.
31, 2015, follows at the end of this release.
KEY RATING DRIVERS
Strong Market Share: OMI holds a strong share of the steady and
oligopolistic
market for the di
Read more
BRIEF-Blackstone said in takeover talks with Concordia Healthcare- StreetInsider citing Bloomberg
* Blackstone Said In Takeover Talks With Concordia
Healthcare - Streetinsider citing bloomberg
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
Healthcare - Streetinsider citing bloomberg
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
Gap in death rates between rich and poor young Americans narrows -study
WASHINGTON, April 21 (Reuters) - Death rates for U.S.
infants, children, teenagers and young adults are falling,
particularly among those in poor regions, likely due to social
policies that have helped the most disadvantaged families,
researchers said on Thursday.
Read more
infants, children, teenagers and young adults are falling,
particularly among those in poor regions, likely due to social
policies that have helped the most disadvantaged families,
researchers said on Thursday.
Read more
Walgreens, Duane Reade settle NY overcharge probe
April 21 (Reuters) - Walgreen Co agreed to pay $500,000 and
reform its advertising practices to settle allegations its
Walgreens and Duane Reade stores in New York routinely
overcharged consumers and tricked them into thinking they were
getting great deals.
Read more
reform its advertising practices to settle allegations its
Walgreens and Duane Reade stores in New York routinely
overcharged consumers and tricked them into thinking they were
getting great deals.
Read more
Deals of the day- Mergers and acquisitions
April 21 (Reuters) - The following bids, mergers,
acquisitions and disposals were reported by 1400 GMT on
Thursday:
Read more
acquisitions and disposals were reported by 1400 GMT on
Thursday:
Read more
BRIEF-Ultragenyx reports positive interim data from Phase 2 study of KRN23
* Reports positive interim data from Phase 2 study of KRN23
for the treatment of tumor-induced osteomalacia
Read more
for the treatment of tumor-induced osteomalacia
Read more
Zika, dengue fever pose "immediate threat" in quake-hit Ecuador-charity
LONDON, April 21 (Thomson Reuters Foundation) -
M osquito-borne diseases including the Zika virus and dengue
fever pose an "immediate threat" to survivors of the devastating
earthquake that hit Ecuador four days ago, an international
charity said on Thursday.
Read more
M osquito-borne diseases including the Zika virus and dengue
fever pose an "immediate threat" to survivors of the devastating
earthquake that hit Ecuador four days ago, an international
charity said on Thursday.
Read more
BRIEF-FDA staff maintains negative outlook on Sarepta's DMD drug
* FDA staff says it does not agree with Sarepta's
characterization of inaccuracies in the initial FDA briefing
document
Read more
characterization of inaccuracies in the initial FDA briefing
document
Read more
BRIEF-Hologic announces FDA clearance of Affirm Prone Biopsy System
* announces FDA clearance and commercial availability Of
Affirm Prone Biopsy System, First 2d/3d Imaging Guided
dedicated prone biopsy system
Read more
Affirm Prone Biopsy System, First 2d/3d Imaging Guided
dedicated prone biopsy system
Read more
IHH Healthcare Berhad buys hospitals in Bulgaria
SOFIA, April 21 (Reuters) - Malaysia-based IHH Healthcare
Berhad is to buy Bulgaria's Tokuda Hospital in a deal
that will help to make it the biggest private healthcare
provider in the Balkan country, the company said on Thursday.
Read more
Berhad is to buy Bulgaria's Tokuda Hospital in a deal
that will help to make it the biggest private healthcare
provider in the Balkan country, the company said on Thursday.
Read more
BRIEF-PDL Biopharma says CEO John Mclaughlin's 2015 compensation was $3.9 mln
* Says CEO John Mclaughlin's 2015 total compensation was
$3.9 million versus $4.1 million in 2014 - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
$3.9 million versus $4.1 million in 2014 - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-Novartis sees 2016 Entresto sales of about $200 mln
* Says expects 2016 entresto sales of about $200 million
Source text for Eikon:
Further company coverage:
(Reporting by John Miller)
Read more
Source text for Eikon:
Further company coverage:
(Reporting by John Miller)
Read more
BRIEF-Kancera is to acquire Fractalkine project
* Payment for Fractalkine project to Acturum Life Science AB is to be carried in three steps
with total of 6 million shares
Read more
with total of 6 million shares
Read more
Wednesday, April 20, 2016
BRIEF-Fibrogen says phase 2 data show Roxadustat corrected Anemia in chronic kidney disease patients before intervention with dialysis
* Promising phase 2 data show Roxadustat corrected Anemia in
chronic kidney disease patients before intervention with
dialysis
Read more
chronic kidney disease patients before intervention with
dialysis
Read more
BRIEF-THERAMetrics posts FY net loss of 8.5 million euros
* Generated revenues of 13.8 million euros ($15.58 million)
and net loss of 8.5 million euros for year ended Dec. 31, 2015,
compared to revenues of 16.2 million euros and net loss of 10.2
million euros for year ended Dec. 31, 2014
Read more
and net loss of 8.5 million euros for year ended Dec. 31, 2015,
compared to revenues of 16.2 million euros and net loss of 10.2
million euros for year ended Dec. 31, 2014
Read more
PRESS DIGEST- British Business - April 21
April 21 (Reuters) - The following are the top stories on
the business pages of British newspapers. Reuters has not
verified these stories and does not vouch for their accuracy.
Read more
the business pages of British newspapers. Reuters has not
verified these stories and does not vouch for their accuracy.
Read more
BRIEF-Helix Biopharma says Patrick Frankham appointed COO
* Patrick frankham appointed chief operating officer
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
PRESS DIGEST- Financial Times - April 21
April 21 (Reuters) - The following are the top stories in
the Financial Times. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
the Financial Times. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
BRIEF-Hemostemix announces non-brokered private placement
* Says non-brokered private placement offering, which will
consist of issuance of up to 12,500,000 units at of $0.40 per
unit
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
consist of issuance of up to 12,500,000 units at of $0.40 per
unit
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Stryker reports Q1 adjusted earnings per share $1.24
* Now expect 2016 adjusted net earnings per diluted share to
be in range of $5.65-$5.80, compared to our prior guidance of
$5.57 - $5.77
Read more
be in range of $5.65-$5.80, compared to our prior guidance of
$5.57 - $5.77
Read more
Fitch: Senior U.S. CLO Notes Still Insulated From Downgrades
(The following statement was released by the rating agency)
Link to Fitch Ratings' Report: U.S. CLO Index: Par and OC
Cushions Continue to
Decline in U.S. CLOs
https://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=880263
CHICAGO, April 20 (Fitch) Fewer U.S. CLOs are escaping the
rising number of
defaulted issuers, though Fitch rated 'AAA' tranches should
remain shielded from
potential downgrades, according to Fitch Ratings in its latest
U.S. CLO index.
Approximately 70% of 2
Read more
Link to Fitch Ratings' Report: U.S. CLO Index: Par and OC
Cushions Continue to
Decline in U.S. CLOs
https://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=880263
CHICAGO, April 20 (Fitch) Fewer U.S. CLOs are escaping the
rising number of
defaulted issuers, though Fitch rated 'AAA' tranches should
remain shielded from
potential downgrades, according to Fitch Ratings in its latest
U.S. CLO index.
Approximately 70% of 2
Read more
What to Watch in the Day Ahead - Thursday, April 21
(The Day Ahead is an email and PDF publication that includes the day's major stories and
events, analyses and other features. To receive The Day Ahead, Eikon users can register at
. Thomson One users can register at RT/DAY/US. All times in ET/GMT)
Alphabet Inc is expected to report a rise in first-quarter revenue that is likely to beat
analysts average estimate, according to Thomson Reuters StarMine data. Investors will be looking
for continued growth at Alphabet's Google unit, which has
Read more
REFILE-UPDATE 2-Heart failure devices pump up St. Jude's profit, revenue
April 20 (Reuters) - St. Jude Medical Inc reported
better-than-expected quarterly results helped by strong heart
failure device sales and said it was making progress in getting
its pacemaker and defibrillator business back on track.
Read more
better-than-expected quarterly results helped by strong heart
failure device sales and said it was making progress in getting
its pacemaker and defibrillator business back on track.
Read more
BRIEF-AmpliPhi Biosciences provides update on phage therapy Phase I trial
* AmpliPhi Biosciences provides update on Phase I trial:
phage therapy well tolerated in first cohort
Read more
phage therapy well tolerated in first cohort
Read more
BRIEF-Genticel announces additional results at 12 months for phase 2 of GTL001
* Announces additional results at 12 months for phase 2 of
GTL001
Source text: http://bit.ly/1YH6vUR
Further company coverage:
(Gdynia Newsroom)
Read more
GTL001
Source text: http://bit.ly/1YH6vUR
Further company coverage:
(Gdynia Newsroom)
Read more
UPDATE 1-Canada plans marijuana decriminalization by spring 2017 -minister
TORONTO, April 20 (Reuters) - Canada's Liberal government
will introduce legislation to decriminalize and regulate
recreational marijuana in spring 2017, Health Minister Jane
Philpott said on Wednesday.
Read more
will introduce legislation to decriminalize and regulate
recreational marijuana in spring 2017, Health Minister Jane
Philpott said on Wednesday.
Read more
BRIEF-American Renal Associates sees IPO of 7.5 mln shares priced at $20-$23 each
* American Renal Associates Holdings Inc sees IPO of 7.5 mln
shares of its common stock priced between $20 $23 each - SEC
filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
shares of its common stock priced between $20 $23 each - SEC
filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-Pfizer Canada says partnered with Rexall in new service called OneStopMeds
* Partnered with Rexall in service called OneStopMeds to
improve medication adherence for patients taking multiple
chronic medications
Source text for Eikon:
Further company coverage:
Read more
improve medication adherence for patients taking multiple
chronic medications
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Cytrx to present new clinical data on its cancer drug
* Cytrx to present updated aldoxorubicin clinical trial data
at the American Society of Clinical Oncology Annual Meeting in
June 2016
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
at the American Society of Clinical Oncology Annual Meeting in
June 2016
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-VolitionRx says diagnostic test detected 71 pct of early stage I prostate cancer cases
* VolitionRx announces study results showing NUQ blood test
detects prostate cancer early with significantly higher accuracy
than PSA test
Read more
detects prostate cancer early with significantly higher accuracy
than PSA test
Read more
BRIEF-Owens & Minor Distribution sees FY 2016 adj EPS $2.00 to $2.05
* Distribution agreement between Owens & Minor and a large
national healthcare provider customer will not be renewed; O&M
reaffirms financial outlook for 2016
Read more
national healthcare provider customer will not be renewed; O&M
reaffirms financial outlook for 2016
Read more
BRIEF-Biomarin provides preliminary data on first 8 patients in Hemophilia A gene therapy program
* Biomarin provides encouraging preliminary data on first 8
patients in hemophilia a gene therapy program
Read more
patients in hemophilia a gene therapy program
Read more
Medical device maker St. Jude reports 7.6 pct rise in revenue
April 20 (Reuters) - St. Jude Medical Inc reported a
7.6 percent rise in quarterly revenue, helped by higher sales in
its heart failure and neuromodulation businesses.
Read more
7.6 percent rise in quarterly revenue, helped by higher sales in
its heart failure and neuromodulation businesses.
Read more
BRIEF-Aralez says conducted bioequivalence studies comparing Aspirin from old and new suppliers
* Conducted human bioequivalence studies comparing aspirin
drug manufactured from original aspirin supplier to new primary
aspirin supplier
Read more
drug manufactured from original aspirin supplier to new primary
aspirin supplier
Read more
BRIEF-Acorda announces results from mid-phase clinical trial of CVT-301
* Acorda Announces Results From Phase 2b Clinical Trial Of
CVT 301 for treatment of off periods in parkinson's disease
published in movement disorders
Read more
CVT 301 for treatment of off periods in parkinson's disease
published in movement disorders
Read more
BRIEF-Feelgood Svenska proposes Göran Hägglund as chairman
April 20 (Reuters) - Feelgood Svenska publ AB :
* Proposes Göran Hägglund as new chairman
* Jan-Erik Karlsson declined re-election as chairman
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-KNF approves Airway Medix's prospectus for WSE's main market listing
* Said on Tuesday that it approved prospectus submitted by
Airway Medix SA related to plans of listing of series A
and B shares on regulated market of the Warsaw Stock Exchange
Read more
Airway Medix SA related to plans of listing of series A
and B shares on regulated market of the Warsaw Stock Exchange
Read more
BRIEF-Oculus Innovative Sciences receives U.S. FDA approval for Lasercyn
* Oculus Innovative Sciences receives U.S. FDA approval for Lasercyn(tm) for use following
laser procedures, microdermabrasions and chemical peels
Read more
laser procedures, microdermabrasions and chemical peels
Read more
Nestle extends pharma push with new bet on gut drugs
April 20 (Reuters) - Nestle has extended its push
into medicine with a small investment in a biotech company
developing a drug designed to fight inflammatory bowel disease
by restoring a healthy bacteria balance in the gut.
Read more
into medicine with a small investment in a biotech company
developing a drug designed to fight inflammatory bowel disease
by restoring a healthy bacteria balance in the gut.
Read more
BRIEF-Cantargia raises SEK 31.4 mln through exercise of warrants
* Cantargia raises 31.4 million Swedish crowns through
exercise of warrants of series TO 1 and TO 3
Read more
exercise of warrants of series TO 1 and TO 3
Read more
Tuesday, April 19, 2016
BRIEF-Formycon FY net profit at 0.57 million euros
* Increased its turnover in 2015 by 34 percent compared to
previous year, from 12.58 million euros ($14.28 million) to 16.9
million euros
Read more
previous year, from 12.58 million euros ($14.28 million) to 16.9
million euros
Read more
Barco Q1 sales up on strong healthcare, enterprise units
BRUSSELS, April 20 (Reuters) - Belgian digital display
company Barco said on Wednesday its order book and
quarterly sales had increased compared to the same period last
year with growth in its units making products for hospitals and
control rooms.
Read more
company Barco said on Wednesday its order book and
quarterly sales had increased compared to the same period last
year with growth in its units making products for hospitals and
control rooms.
Read more
PRESS DIGEST- British Business - April 20
April 20 (Reuters) - The following are the top stories on
the business pages of British newspapers. Reuters has not
verified these stories and does not vouch for their accuracy.
Read more
the business pages of British newspapers. Reuters has not
verified these stories and does not vouch for their accuracy.
Read more
UPDATE 2-Intuitive Surgical boosts procedure growth forecast
April 19 (Reuters) - Intuitive Surgical Inc on
Tuesday reported better-than-expected first-quarter profit on
expanded use of its da Vinci robots in U.S. general surgeries
such as hernia repair, and it raised its full-year outlook for
procedure growth.
Read more
Tuesday reported better-than-expected first-quarter profit on
expanded use of its da Vinci robots in U.S. general surgeries
such as hernia repair, and it raised its full-year outlook for
procedure growth.
Read more
Global HIV drive hampered without drugs for "neglected" West and Central Africa
DAKAR, April 20 (Thomson Reuters Foundation) - A global
drive to help curb the HIV epidemic by 2020 will fail unless
millions of people with the virus in West and Central Africa
receive life-saving drugs, Medecins Sans Frontieres (MSF) said
on Wednesday.
Read more
drive to help curb the HIV epidemic by 2020 will fail unless
millions of people with the virus in West and Central Africa
receive life-saving drugs, Medecins Sans Frontieres (MSF) said
on Wednesday.
Read more
UnitedHealth's Obamacare exit adds pricing pressure on rivals
NEW YORK, April 19 (Reuters) - UnitedHealth Group Inc's
decision to exit most of its Obamacare health insurance
exchanges next year means rivals will need to raise prices
further to prop up an unprofitable business, healthcare analysts
and policy experts said on Tuesday.
Read more
decision to exit most of its Obamacare health insurance
exchanges next year means rivals will need to raise prices
further to prop up an unprofitable business, healthcare analysts
and policy experts said on Tuesday.
Read more
UPDATE 1-U.S. pledges $40 mln to countries affected by Boko Haram
YAOUNDE, April 19 (Reuters) - The United States will give
$40 million in humanitarian assistance to countries bordering
Lake Chad fighting Islamist militant group Boko Haram, U.S.
ambassador to the United Nations Samantha Power said on Tuesday.
Read more
$40 million in humanitarian assistance to countries bordering
Lake Chad fighting Islamist militant group Boko Haram, U.S.
ambassador to the United Nations Samantha Power said on Tuesday.
Read more
BRIEF-Corvus Pharmaceuticals announce results of preclinical studies
* Corvus Pharmaceuticals announces results of preclinical
studies demonstrating enhanced immune responses and anti-tumor
activity with CPI-444, an investigational immuno-oncology
therapy
Read more
studies demonstrating enhanced immune responses and anti-tumor
activity with CPI-444, an investigational immuno-oncology
therapy
Read more
BRIEF-Supernus Pharmaceuticals CEO 2015 total compensation $3.2 mln
* CEO Jack A. Khattar's 2015 total compensation was $3.2
million versus $1.7 million in 2014 - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
million versus $1.7 million in 2014 - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Intuitive Surgical boosts outlook for 2016 procedure growth
April 19 (Reuters) - INTUITIVE SURGICAL RAISES OUTLOOK FOR
2016 PROCEDURE GROWTH TO RANGE OF 12-14 PERCENT
INTUITIVE SURGICAL PREVIOUSLY FORECAST 2016 PROCEDURE GROWTH AT
9-12 PERCENT
INTUITIVE SAYS INCREASE DUE TO FAVORABLE U.S. PROSTATE,
GYNECOLOGICAL SURGERY OUTLOOK
(Reporting by Susan Kelly in Chicago)
Read more
2016 PROCEDURE GROWTH TO RANGE OF 12-14 PERCENT
INTUITIVE SURGICAL PREVIOUSLY FORECAST 2016 PROCEDURE GROWTH AT
9-12 PERCENT
INTUITIVE SAYS INCREASE DUE TO FAVORABLE U.S. PROSTATE,
GYNECOLOGICAL SURGERY OUTLOOK
(Reporting by Susan Kelly in Chicago)
Read more
Express Scripts says Anthem negotiated in bad faith -court filing
April 19 (Reuters) - Pharmacy benefit manager Express
Scripts Holding Co has accused Anthem Inc of
negotiating their contract in bad faith and is seeking a court
order that the health insurer has no right to demand lower drug
prices.
Read more
Scripts Holding Co has accused Anthem Inc of
negotiating their contract in bad faith and is seeking a court
order that the health insurer has no right to demand lower drug
prices.
Read more
UPDATE 3-J&J shares hit new high on strong drug sales, weaker dollar
April 19 (Reuters) - Johnson & Johnson beat
quarterly earnings forecasts on strong prescription drug revenue
and a weakening dollar, and it reassured investors that it did
not expect its blockbuster Remicade arthritis drug to face U.S.
competition this year.
Read more
quarterly earnings forecasts on strong prescription drug revenue
and a weakening dollar, and it reassured investors that it did
not expect its blockbuster Remicade arthritis drug to face U.S.
competition this year.
Read more
UPDATE 1-UN reviews war on drugs amid global push for liberalization
UNITED NATIONS, April 19 (Reuters) - The U.N. General
Assembly gathered on Tuesday to rethink global strategy in the
war on narcotics for the first time in two decades as activists,
U.N. officials and world leaders cited an international trend
towards more liberal drug laws.
Read more
Assembly gathered on Tuesday to rethink global strategy in the
war on narcotics for the first time in two decades as activists,
U.N. officials and world leaders cited an international trend
towards more liberal drug laws.
Read more
BRIEF-Abivax gets clearance in Spain for second phase IIa trial in HIV/AIDS patients
* Abivax obtains regulatory and ethics clearance in Spain to
begin second phase iia clinical trial for ABX464 in HIV/AIDS
patients
Read more
begin second phase iia clinical trial for ABX464 in HIV/AIDS
patients
Read more
REFILE-UN reviews war on drugs amid global push for liberalization
UNITED NATIONS, April 19 (Reuters) - The U.N. General
Assembly gathered on Tuesday to rethink global strategy in the
war on narcotics for the first time in two decades as activists,
U.N. officials and world leaders cited an international trend
towards more liberal drug laws.
Read more
Assembly gathered on Tuesday to rethink global strategy in the
war on narcotics for the first time in two decades as activists,
U.N. officials and world leaders cited an international trend
towards more liberal drug laws.
Read more
BRIEF-Vetoquinol Q1 sales up at 85.8 mln euros
* Q1 2016 sales are 85.8 million euros, representing organic
growth of 7.7 pct
Source text for Eikon:
Further company coverage:
($1 = 0.8794 euros)
(Gdynia Newsroom)
Read more
growth of 7.7 pct
Source text for Eikon:
Further company coverage:
($1 = 0.8794 euros)
(Gdynia Newsroom)
Read more
BRIEF-J&J says does not expect Remicade to face competition from U.S. biosimilar this year
* Says in conference call that he does not expect Remicade
sales to be hurt by biosimilars this year in United States
Read more
sales to be hurt by biosimilars this year in United States
Read more
MIDEAST STOCKS-Saudi earnings, oil boost Gulf, Egypt breaks chart barrier
DUBAI, April 19 (Reuters) - Gulf stock markets rose on
Tuesday as several Saudi companies beat first-quarter earnings
estimates and oil prices held up better than feared after the
failure of Sunday's Doha meeting to agree on an output freeze.
Read more
Tuesday as several Saudi companies beat first-quarter earnings
estimates and oil prices held up better than feared after the
failure of Sunday's Doha meeting to agree on an output freeze.
Read more
Bristol-Myers' Opdivo extends survival in head and neck cancer -study
April 19 (Reuters) - Bristol-Myers Squibb's cancer
immunotherapy drug, Opdivo, helped advanced head and neck cancer
patients with a dismal prognosis live longer than other standard
treatments, according to data from a late-stage study presented
on Tuesday.
Read more
immunotherapy drug, Opdivo, helped advanced head and neck cancer
patients with a dismal prognosis live longer than other standard
treatments, according to data from a late-stage study presented
on Tuesday.
Read more
UPDATE 1-Bristol-Myers' Opdivo extends survival in head and neck cancer -study
April 19 (Reuters) - Bristol-Myers Squibb's cancer
immunotherapy drug, Opdivo, helped advanced head and neck cancer
patients with a dismal prognosis live longer than other standard
treatments, according to data from a late-stage study presented
on Tuesday.
Read more
immunotherapy drug, Opdivo, helped advanced head and neck cancer
patients with a dismal prognosis live longer than other standard
treatments, according to data from a late-stage study presented
on Tuesday.
Read more
UnitedHealth to exit all but a handful of Obamacare exchanges in 2017 -CEO
NEW YORK, April 19 (Reuters) - UnitedHealth Group Inc
Chief Executive Officer Steven Hemsley said on Tuesday
that the company would largely exit the Obamacare exchange
market in 2017, following through on a warning he had given late
last year that costs appeared to be unsustainable.
Read more
Chief Executive Officer Steven Hemsley said on Tuesday
that the company would largely exit the Obamacare exchange
market in 2017, following through on a warning he had given late
last year that costs appeared to be unsustainable.
Read more
BRIEF-Loxo Oncology announces first pediatric response to LOXO-101
* Loxo Oncology Announces First Pediatric Response to
LOXO-101, it induces 90 percent tumor regression in toddler with
refractory infantile fibrosarcoma
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
LOXO-101, it induces 90 percent tumor regression in toddler with
refractory infantile fibrosarcoma
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Sucampo says to discontinue development of Cobiprostone for PPI-Refractory NERD/SGERD
* Sucampo reports top-line data from phase 2a study of
cobiprostone in patients with PPI-Refractory Non-Erosive Reflux
Disease (NERD) and Symptomatic Gastroesophageal Reflux Disease
(SGERD)
Read more
cobiprostone in patients with PPI-Refractory Non-Erosive Reflux
Disease (NERD) and Symptomatic Gastroesophageal Reflux Disease
(SGERD)
Read more
BRIEF-RXI Pharmaceuticals says received notice of allowance for RXI-109 from USPTO
* RXI Pharmaceuticals says fortifies its novel RNAi patent
portfolio with notice of allowance for lead clinical candidate
RXI-109
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
portfolio with notice of allowance for lead clinical candidate
RXI-109
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
RPT-DEALTALK-Debt-laden Valeant faces tough choices in asset sales
NEW YORK, April 19 (Reuters) - As Valeant Pharmaceuticals
considers a multibillion-dollar auction to pare down $30 billion
in debt, its challenge will be choosing which assets to sell
without compromising any of its key businesses, analysts and
investment bankers said.
Read more
considers a multibillion-dollar auction to pare down $30 billion
in debt, its challenge will be choosing which assets to sell
without compromising any of its key businesses, analysts and
investment bankers said.
Read more
Health insurer UnitedHealth reports higher profit
April 19 (Reuters) - Health insurer UnitedHealth Group Inc
reported a 14 percent rise in quarterly profit helped by
strength in its Optum business which offers healthcare services
and drug benefit plans.
Read more
reported a 14 percent rise in quarterly profit helped by
strength in its Optum business which offers healthcare services
and drug benefit plans.
Read more
UPDATE 1-Health insurer UnitedHealth reports better-than-expected revenue
April 19 (Reuters) - Health insurer UnitedHealth Group Inc
reported a better-than-expected quarterly revenue helped
by strength in its Optum business which offers healthcare
services and drug benefit plans.
Read more
reported a better-than-expected quarterly revenue helped
by strength in its Optum business which offers healthcare
services and drug benefit plans.
Read more
BRIEF-Eli Lilly says Jardiance to be studied for treatment of chronic heart failure
* Trials targeted to begin within next 12 months and planned
to enroll people with chronic heart failure both with and
without type 2 diabetes
Read more
to enroll people with chronic heart failure both with and
without type 2 diabetes
Read more
BRIEF-Episurf Medical gets expanded reimbursement coverage in UK, Netherlands and Belgium
* Receives expanded reimbursement coverage in the UK, Netherlands and Belgium
Source text for Eikon:
Read more
Source text for Eikon:
Read more
BRIEF-Hansa Medical: recruitment completed in Phase II clinical study with IdeS in kidney transplantation
* Patient recruitment completed in Phase II clinical study with IdeS in kidney
transplantation
Read more
transplantation
Read more
Monday, April 18, 2016
BRIEF-Biofrontera says capital increase several times oversubscribed
* Said on Monday that capital increase resolved on March 29,
2016 was several times oversubscribed
Read more
2016 was several times oversubscribed
Read more
BRIEF-Onxeo reports positive data for Livatag
* Reported on Monday the final data from a study aiming to
confirm the mechanism of action of Livatag
Read more
confirm the mechanism of action of Livatag
Read more
BRIEF-Biotec Pharmacon Q1 EBITDA widens to loss NOK 3.5 mln
* Q1 revenue 17.3 million Norwegian crowns ($2.11
million)versus 12.3 million crowns year ago
Read more
million)versus 12.3 million crowns year ago
Read more
Sanofi invests 300 mln eur to expand Belgian plant
PARIS, April 19 (Reuters) - Sanofi said on Tuesday
that it would invest 300 million euros ($339 million) to expand
a Belgian site specialised in making treatments for rare
diseases.
Read more
that it would invest 300 million euros ($339 million) to expand
a Belgian site specialised in making treatments for rare
diseases.
Read more
Bill Gates says U.S. needs limits on covert email searches
WASHINGTON, April 18 (Reuters) - Bill Gates said on Monday
that no one was an "absolutist" on either side of the digital
privacy debate, but the co-founder of Microsoft Corp
said he supports his company's lawsuit against the U.S.
government seeking the freedom to tell customers when federal
agencies have sought their data.
Read more
that no one was an "absolutist" on either side of the digital
privacy debate, but the co-founder of Microsoft Corp
said he supports his company's lawsuit against the U.S.
government seeking the freedom to tell customers when federal
agencies have sought their data.
Read more
BRIEF-Theranos says investigations or inspections were opened by CMS, FDA, SEC, and the U.S. Attorney's office for the Northern District of California
* Theranos says investigations or inspections were opened by
CMS, FDA, SEC, and the U.S. Attorney's office for the Northern
District of California
Read more
CMS, FDA, SEC, and the U.S. Attorney's office for the Northern
District of California
Read more
BRIEF-Dicerna announces appointment of John Green as CFO
* Dicerna announces appointment of john "jack" green as
chief financial officer
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
chief financial officer
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Theranos under investigation by SEC and U.S. Attorney's Office -Bloomberg
April 18 (Reuters) - Blood-testing firm Theranos Inc is
under investigation by the U.S. Securities and Exchange
Commission and the U.S. Attorney's Office for the Northern
District of California, Bloomberg reported.
Read more
under investigation by the U.S. Securities and Exchange
Commission and the U.S. Attorney's Office for the Northern
District of California, Bloomberg reported.
Read more
BRIEF-Leonard Potter reports 6.8 pct stake in Sorrento Therapeutics
* Leonard Potter reports 6.8 percent stake in Sorrento
Therapeutics Inc as of April 8 - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Therapeutics Inc as of April 8 - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Dynavax presents pivotal phase 3 data showing HEPLISAV-B provides significantly higher protection against Hepatitis B than ENGERIX-B(R)
* Dynavax presents pivotal phase 3 data showing
heplisav-b(tm) provides significantly higher protection against
hepatitis b than engerix-b(r)
Read more
heplisav-b(tm) provides significantly higher protection against
hepatitis b than engerix-b(r)
Read more
What to Watch in the Day Ahead - Tuesday, April 19
(The Day Ahead is an email and PDF publication that includes the day's major stories and
events, analyses and other features. To receive The Day Ahead, Eikon users can register at
. Thomson One users can register at RT/DAY/US. All times in ET/GMT)
Johnson & Johnson is expected to report moderately higher earnings as it kicks off the
first-quarter earnings season for large U.S. drugmakers, bolstered by cost cuts and growing
sales of its treatments for cancer, arthritis and psoriasis. But investo
Read more
events, analyses and other features. To receive The Day Ahead, Eikon users can register at
. Thomson One users can register at RT/DAY/US. All times in ET/GMT)
Johnson & Johnson is expected to report moderately higher earnings as it kicks off the
first-quarter earnings season for large U.S. drugmakers, bolstered by cost cuts and growing
sales of its treatments for cancer, arthritis and psoriasis. But investo
Read more
BRIEF-Sienna Senior Living purchases assets for about $255 mln in British Columbia
* Sienna Senior Living announces significant expansion in
British Columbia and $120 million bought deal public offering of
subscription receipts
Read more
British Columbia and $120 million bought deal public offering of
subscription receipts
Read more
BRIEF-Nihon Chouzai expectes operating profit of around 10 bln Yen for FY ended March 31 - Nikkei
* Nihon Chouzai is expected to report an operating profit of
around 10 bln yen ($91.9 million) for FY ended March 31 - Nikkei
Read more
around 10 bln yen ($91.9 million) for FY ended March 31 - Nikkei
Read more
BRIEF-Wong Chi-Huey withdraws resignation amid insider trading probe - Nikkei
* Taiwan's Academia Sinica President Wong Chi-Huey withdrew
resignation, pledged to answer queries on insider trading probe
related to Obi Pharma - Nikkei
Source text http://s.nikkei.com/1SnltxA
Further company coverage:
Read more
resignation, pledged to answer queries on insider trading probe
related to Obi Pharma - Nikkei
Source text http://s.nikkei.com/1SnltxA
Further company coverage:
Read more
BRIEF-Tesaro says has sold $50 million in equity financing - SEC Filing
* Discloses in Form D with U.S. SEC that the total offering
amount was for $50 million - SEC Filing
Source - http://1.usa.gov/1NiJEhB
Further company coverage:
(Bengaluru Newsroom; +1 646 223 8780)
Read more
amount was for $50 million - SEC Filing
Source - http://1.usa.gov/1NiJEhB
Further company coverage:
(Bengaluru Newsroom; +1 646 223 8780)
Read more
BRIEF-Pieris Pharmaceuticals enters into agreement with Enumeral Biomedical Holdings
* Co entered into a license and transfer agreement with
Enumeral Biomedical Holdings
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Enumeral Biomedical Holdings
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Deals of the day- Mergers and acquisitions
April 18 (Reuters) - The following bids, mergers,
acquisitions and disposals were reported by 1345 GMT on Monday:
Read more
acquisitions and disposals were reported by 1345 GMT on Monday:
Read more
BRIEF-Cytori Therapeutics says announced additions to patent portfolio in Japan and Europe
* Says announced today a number of key additions to its
patent portfolio in Japan and Europe
Read more
patent portfolio in Japan and Europe
Read more
BRIEF-Geovax says MVA-VLP vaccine vector has proven safe in multiple human clinical trials
* Geovax Labs inc says "vaccine construction is progressing
rapidly" and we expect to initiate animal studies next month
Read more
rapidly" and we expect to initiate animal studies next month
Read more
BRIEF-Infinity Pharma announces new preclinical data for IPI-549
* Preclinical data demonstrate that ipi-549 targets immune
cells, alters immune-suppressive microenvironment
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
cells, alters immune-suppressive microenvironment
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Fibrocell Science receives allowance from U.S. FDA to initiate a phase I/II clinical trial of FCX-007 in adults
* Received allowance from u.s. Food and drug administration
(fda) to initiate a phase i/ii clinical trial of fcx-007 in
adults
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
(fda) to initiate a phase i/ii clinical trial of fcx-007 in
adults
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
COLUMN-America's Secret Weapon
April 18 (Reuters) - This presidential election has the
country captivated. As many commentators have pointed out, the
primaries are more focused on personalities than policy. While
the parties focus on who is going to represent them in the fall,
I want to make the case for something that I hope every
candidate will agree on in November: America's unparalleled
capacity for innovation. When the United States invests in
innovation, it creates companies and jobs at home, makes
Americans healthier a
Read more
country captivated. As many commentators have pointed out, the
primaries are more focused on personalities than policy. While
the parties focus on who is going to represent them in the fall,
I want to make the case for something that I hope every
candidate will agree on in November: America's unparalleled
capacity for innovation. When the United States invests in
innovation, it creates companies and jobs at home, makes
Americans healthier a
Read more
BRIEF-Chiasma updates FDA's complete response letter for Mycapssa(tm)
* Chiasma provides update regarding FDA's complete response
letter for Mycapssa(tm) new drug application
Read more
letter for Mycapssa(tm) new drug application
Read more
Is your weed killer carcinogenic?
LONDON, April 18 (Reuters) - The latest dispute to blow up
around the International Agency for Research on Cancer (IARC)
concerns glyphosate, an ingredient in one of the world's most
widely-used weed killers, Roundup, made by Monsanto.
Read more
around the International Agency for Research on Cancer (IARC)
concerns glyphosate, an ingredient in one of the world's most
widely-used weed killers, Roundup, made by Monsanto.
Read more
Afghan schools, hospitals under threat, U.N. says in grim report
KABUL, April 18 (Reuters) - Schools and health facilities
have come under increasing threat as violence spreads in
Afghanistan, making it harder for children especially to get
access to education and medical care, the United Nations
reported on Monday.
Read more
have come under increasing threat as violence spreads in
Afghanistan, making it harder for children especially to get
access to education and medical care, the United Nations
reported on Monday.
Read more
BRIEF-Bioinvent says multiple myeloma phase II study of antibody BI-505 ready to start
* Multiple myeloma phase II study of Bioinvent's antibody
BI-505 ready to start
Source text for Eikon:
Further company coverage:
Read more
BI-505 ready to start
Source text for Eikon:
Further company coverage:
Read more
Sunday, April 17, 2016
PRESS DIGEST- British Business - April 18
April 18 (Reuters) - The following are the top stories on
the business pages of British newspapers. Reuters has not
verified these stories and does not vouch for their accuracy.
Read more
the business pages of British newspapers. Reuters has not
verified these stories and does not vouch for their accuracy.
Read more
BRIEF-Shenzhen Glory Medical signs agreement on healthcare facilities projects
* Says it signs strategic agreement on healthcare facilities
projects with total investment about 600 million yuan in Henan
province
Read more
projects with total investment about 600 million yuan in Henan
province
Read more
UPDATE 1-AstraZeneca has held internal talks for Medivation bid -Sunday Times
April 17 (Reuters) - Drugmaker AstraZeneca Plc has
held internal talks about a bid for cancer treatment maker
Medivation Inc but has yet to make a formal offer, the
Sunday Times reported, citing sources.
Read more
held internal talks about a bid for cancer treatment maker
Medivation Inc but has yet to make a formal offer, the
Sunday Times reported, citing sources.
Read more
BRIEF-Astrazeneca has held internal talks about a bid for Medivation Inc looking very closely at an offer- Sunday Times, citing sources
* Astrazeneca has held internal talks about a bid for
Medivation Inc; looking very closely at an offer- Sunday Times,
citing sources
Source text : (http://bit.ly/1Sfk0Hv)
(Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223
8780)
Read more
Medivation Inc; looking very closely at an offer- Sunday Times,
citing sources
Source text : (http://bit.ly/1Sfk0Hv)
(Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223
8780)
Read more
AstraZeneca has held internal talks for Medivation bid -Sunday Times
April 17 (Reuters) - Drugmaker AstraZeneca Plc has
held internal talks about a bid for Medivation Inc but
has yet to make a formal offer, the Sunday Times reported,
citing sources.
Read more
held internal talks about a bid for Medivation Inc but
has yet to make a formal offer, the Sunday Times reported,
citing sources.
Read more
Local Zika outbreaks in United States "likely" -U.S. official
WASHINGTON, April 17 (Reuters) - The United States is likely
to see outbreaks of the Zika virus, with perhaps dozens or
scores of people affected, said Dr. Anthony Fauci, director of
the U.S. National Institute of Allergy and Infectious Diseases,
on Sunday.
Read more
to see outbreaks of the Zika virus, with perhaps dozens or
scores of people affected, said Dr. Anthony Fauci, director of
the U.S. National Institute of Allergy and Infectious Diseases,
on Sunday.
Read more
RPT-Latest battle to wipe out polio begins with vast vaccine switch
LONDON, April 15 (Reuters) - In a huge immunisation effort
in 150 countries, health teams will on Sunday launch what they
hope will be the final push against polio.
Read more
in 150 countries, health teams will on Sunday launch what they
hope will be the final push against polio.
Read more
Peru reports first case of sexually transmitted Zika virus
LIMA, April 16 (Reuters) - Peruvian health authorities on Saturday reported the first case of the Zika virus having been sexually transmitted in the country, after a resident contracted the disease while traveling in Venezuela and then infected his wife once back in Peru.
Read more
Read more
Saturday, April 16, 2016
Kohl raises refugee concerns before Orban meeting
BERLIN, April 16 (Reuters) - Former German Chancellor Helmut
Kohl says he does not believe Europe can absorb millions of
refugees and has appealed for more cooperation to deal with the
crisis ahead of a meeting with right-wing Hungarian Prime
Minister Viktor Orban.
Read more
Kohl says he does not believe Europe can absorb millions of
refugees and has appealed for more cooperation to deal with the
crisis ahead of a meeting with right-wing Hungarian Prime
Minister Viktor Orban.
Read more
REFILE-UPDATE 1-India's ITC says to resume cigarette production amid health warning row
NEW DELHI, April 16 (Reuters) - India's biggest cigarette
maker ITC Ltd said it would resume production at its
factories "consequent upon" a favourable court order, two weeks
after it decided to shutter its plants over the government's
stringent new packaging rules.
Read more
maker ITC Ltd said it would resume production at its
factories "consequent upon" a favourable court order, two weeks
after it decided to shutter its plants over the government's
stringent new packaging rules.
Read more
India's ITC says to resume cigarette production amid health warning row
NEW DELHI, April 16 (Reuters) - India's biggest cigarette
maker ITC Ltd will soon resume production at its
factories, the company said in a statement, two weeks after it
decided to shutter its plants over the government's stringent
new packaging rules.
Read more
maker ITC Ltd will soon resume production at its
factories, the company said in a statement, two weeks after it
decided to shutter its plants over the government's stringent
new packaging rules.
Read more
Friday, April 15, 2016
UPDATE 1-U.S. FDA rejects Chiasma's drug to treat growth disorder
April 15 (Reuters) - The U.S. Food and Drug Administration
has rejected Chiasma Inc's experimental drug to treat
adults with a type of growth disorder, the company said on
Friday.
Read more
has rejected Chiasma Inc's experimental drug to treat
adults with a type of growth disorder, the company said on
Friday.
Read more
New AbbVie hepatitis C regimen shows high cure rates -studies
April 16 (Reuters) - An experimental once-daily combination
hepatitis C treatment being developed by AbbVie Inc
demonstrated very high cure rates across a wide range of disease
genotypes, according to data presented on Saturday, likely
giving the company a more competitive product if approved.
Read more
hepatitis C treatment being developed by AbbVie Inc
demonstrated very high cure rates across a wide range of disease
genotypes, according to data presented on Saturday, likely
giving the company a more competitive product if approved.
Read more
UPDATE 1-Prince recovering after emergency plane landing due to flu-report
LOS ANGELES, April 15 (Reuters) - Singer Prince was released
from an Illinois hospital on Friday after he was hospitalized
with the flu following an emergency plane landing, celebrity
news outlet TMZ said.
Read more
from an Illinois hospital on Friday after he was hospitalized
with the flu following an emergency plane landing, celebrity
news outlet TMZ said.
Read more
BRIEF-Ligand Pharma reports 39.8 pct active stake in Viking Therapeutics
* Ligand Pharmaceuticals Incorporated reports 39.8 pct
active stake in Viking Therapeutics as of April 13, 2016 - sec
filing
Read more
active stake in Viking Therapeutics as of April 13, 2016 - sec
filing
Read more
U.S. FDA rejects Chiasma's drug to treat growth disorder
April 15 (Reuters) - The U.S. Food and Drug Administration
on Friday rejected Chiasma Inc's drug to treat adults
with a type of growth disorder.
Read more
on Friday rejected Chiasma Inc's drug to treat adults
with a type of growth disorder.
Read more
BRIEF-Presbia files for mixed shelf of up to $75 million - SEC Filing
* Files for mixed shelf of up to $75 million - SEC Filing
Source - http://1.usa.gov/1WwcuND
Further company coverage:
(Bengaluru Newsroom; +1 646 223 8780)
Read more
Source - http://1.usa.gov/1WwcuND
Further company coverage:
(Bengaluru Newsroom; +1 646 223 8780)
Read more
BRIEF-Morgan stanley reports 8.1 pct passive stake in Eagle Pharma
* Morgan Stanley reports 8.1 percent passive stake in Eagle
Pharmaceuticals Inc as of April 5, 2016 - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Pharmaceuticals Inc as of April 5, 2016 - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
What to Watch in the Week Ahead and on Monday, April 18
(The Day Ahead is an email and PDF publication that includes the day's major stories and
events, analyses and other features. To receive The Day Ahead, Eikon users can register at
. Thomson One users can register at RT/DAY/US. All times in ET/GMT)
WEEK AHEAD
Markets have a number of issues to focus on next week, beginning with the outcome of Sunday's
meeting of oil ministers from the major oil producing nations. But nobody should get their hopes
up all that much for a major change in OPEC's pr
Read more
events, analyses and other features. To receive The Day Ahead, Eikon users can register at
. Thomson One users can register at RT/DAY/US. All times in ET/GMT)
WEEK AHEAD
Markets have a number of issues to focus on next week, beginning with the outcome of Sunday's
meeting of oil ministers from the major oil producing nations. But nobody should get their hopes
up all that much for a major change in OPEC's pr
Read more
Fitch Affirms Healthcare Realty Trust at 'BBB'; Outlook Stable
(The following statement was released by the rating agency)
NEW YORK, April 15 (Fitch) Fitch Ratings has affirmed the
ratings of Healthcare
Realty Trust (NYSE: HR) including the Issuer Default Rating
(IDR) at 'BBB'. The
Rating Outlook remains Stable. A full list of rating actions
follows at the end
of this release.
KEY RATING DRIVERS
The affirmation of HR's IDR at 'BBB' reflects the low leverage
and high
fixed-charge coverage and Fitch's view of the durability of the
operating cash
flows f
Read more
NEW YORK, April 15 (Fitch) Fitch Ratings has affirmed the
ratings of Healthcare
Realty Trust (NYSE: HR) including the Issuer Default Rating
(IDR) at 'BBB'. The
Rating Outlook remains Stable. A full list of rating actions
follows at the end
of this release.
KEY RATING DRIVERS
The affirmation of HR's IDR at 'BBB' reflects the low leverage
and high
fixed-charge coverage and Fitch's view of the durability of the
operating cash
flows f
Read more
UPDATE 1-Ivorian football star Drogba threatens legal action over attacks on his charity
DAKAR, April 15 (Thomson Reuters Foundation) - Ivorian
football star Didier Drogba has threatened legal action over
accusations that his charity set up to help children in Africa
had spent less than one percent of money raised on worthwhile
projects.
Read more
football star Didier Drogba has threatened legal action over
accusations that his charity set up to help children in Africa
had spent less than one percent of money raised on worthwhile
projects.
Read more
Renata Hesse to head Justice Department's Antitrust Division
WASHINGTON, April 15 (Reuters) - Renata Hesse, who has been
in the midst of enforcing antitrust law during a surge of
aggressive corporate dealmaking, has been named to head the
Justice Department's Antitrust Division, U.S. Attorney General
Loretta Lynch said on Friday.
Read more
in the midst of enforcing antitrust law during a surge of
aggressive corporate dealmaking, has been named to head the
Justice Department's Antitrust Division, U.S. Attorney General
Loretta Lynch said on Friday.
Read more
UPDATE 1-India's Alkem Labs accused of fudging trial data by German regulator
MUMBAI, April 15 (Reuters) - India's Alkem Laboratories
has been accused by Germany's health regulator of
fudging data on clinical trials of an antibiotic and brain
disorder drug, becoming the third Indian firm to be scrutinised
since 2014 for suspected manipulation of trial data.
Read more
has been accused by Germany's health regulator of
fudging data on clinical trials of an antibiotic and brain
disorder drug, becoming the third Indian firm to be scrutinised
since 2014 for suspected manipulation of trial data.
Read more
UPDATE 1-Ex-NFL star Gault is fined in SEC fraud case, will appeal
April 15 (Reuters) - Willie Gault, the former National Football League wide receiver and Olympic sprinter, was ordered to pay $206,571 to settle a U.S. Securities and Exchange Commission lawsuit over his role in a scheme to inflate the stock price of a heart-monitoring device maker.
Read more
Read more
BRIEF-Ose Pharma and Effimune announce signing of merger treaty
* Ose Pharma and Effimune announce the signing of the merger
treaty to create Ose Immunotherapeutics
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom:)
Read more
treaty to create Ose Immunotherapeutics
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom:)
Read more
BRIEF-21st Century Oncology Holdings Inc expects FY pro forma adjusted EBITDA of $155-$170 million
* Expects to report PRO FORMA adjusted EBITDA of between
$155 million and $170 million for year ended December 31, 2015
Read more
$155 million and $170 million for year ended December 31, 2015
Read more
BRIEF-PTC Therapeutics says NICE recommends Translarna for treatment of patients with nonsense mutation duchenne muscular dystrophy in England
* National institute for health and care excellence
recommended translarna for ambulatory patients with nonsense
mutation duchenne muscular dystrophy
Read more
recommended translarna for ambulatory patients with nonsense
mutation duchenne muscular dystrophy
Read more
BRIEF-Otcpharm to liquidate DONELLE COMPANY LIMITED
* Decides to liquidate DONELLE COMPANY LIMITED
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Latest battle to wipe out polio begins with vast vaccine switch
LONDON, April 15 (Reuters) - In a huge immunisation effort
in 150 countries, health teams will on Sunday launch what they
hope will be the final push against polio.
Read more
in 150 countries, health teams will on Sunday launch what they
hope will be the final push against polio.
Read more
BRIEF-Ocera Therapeutics says two preclinical studies further support its ammonia scavenger OCR-002
April 15 (Reuters) - Ocera Therapeutics Announces
Presentation Of Two Preclinical Studies Further Supporting Its
Ammonia Scavenger Ocr
Read more
Presentation Of Two Preclinical Studies Further Supporting Its
Ammonia Scavenger Ocr
Read more
BRIEF-Marinus Pharmaceuticals' ganaxolone IV receives FDA orphan drug designation
* Marinus Pharmaceuticals receives FDA orphan drug
designation for ganaxolone IV to treat status epilepticus
Read more
designation for ganaxolone IV to treat status epilepticus
Read more
WIDER IMAGE-Students run mobile amputee clinic in Syria
Maaret al-Numan, SYRIA, April 14 (Reuters) - In what looks
like an ordinary white truck, two men are helping victims who
have lost limbs in the conflict in Syria to walk, play, and even
herd sheep again.
Read more
like an ordinary white truck, two men are helping victims who
have lost limbs in the conflict in Syria to walk, play, and even
herd sheep again.
Read more
Deals of the day- Mergers and acquisitions
April 15 (Reuters) - The following bids, mergers,
acquisitions and disposals were reported by 1200 GMT on Friday:
Read more
acquisitions and disposals were reported by 1200 GMT on Friday:
Read more
Subscribe to:
Posts (Atom)